PTA Peripheral DCB Catheters Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
PTA Peripheral DCB Catheters Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Summary
GlobalData's Medical Devices sector report, “PTA Peripheral DCB Catheters Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update provides comprehensive information about the PTA Peripheral DCB Catheters pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
A PTA Peripheral DCB Catheter is a drug-coated percutaneous transluminal angioplasty (PTA) balloon intended to prevent restenosis, or restenosis of the peripheral arteries. PTA Peripheral DCB catheters provide fast, short-term, homogenous, local drug delivery to the vessel wall, while preserving the anatomy of the vessel, promoting enhanced vessel healing, and reducing the need for prolonged dual antiplatelet therapy. They can be used to treat native and in-stent restenosis (ISR), bifurcations, small vessels, and long lesions.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the PTA Peripheral DCB Catheters under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of PTA Peripheral DCB Catheters and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of PTA Peripheral DCB Catheters under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date
1 About GlobalData
2 Table of Contents
2.1 List of Tables
2.2 List of Figures
3 Introduction
3.1 PTA Peripheral DCB Catheters Overview
4 Products under Development
4.1 PTA Peripheral DCB Catheters - Pipeline Products by Stage of Development
4.2 PTA Peripheral DCB Catheters - Pipeline Products by Territory
7.22 Aug 26, 2023: Medtronic Q2 2024 Earnings Estimates Increased by William Blair
7.23 Aug 08, 2023: Medtronic to Announce Financial Results for its First Quarter of Fiscal Year 2024
7.24 Aug 07, 2023: MCRA Aids Surmodics in Obtaining FDA Pre-market Approval for Cardiovascular Drug-Coated Balloon
7.25 Jul 21, 2023: Medtronic Statement on the Safety of Paclitaxel Coated Devices to Treat Peripheral Arterial Disease
7.26 Jul 19, 2023: Boston Scientific lays off 52 workers as it closes another Silicon Valley facility
7.27 Jul 13, 2023: BIOPACT RCT Subgroup Analyses Show Consistently Great Results for Passeo-18 Lux Drug-Coated Balloon
7.28 Jun 07, 2023: Endovastec Participates in the Congresso International de Cirurgia Endovascular
7.29 May 30, 2023: Excellent 12-Month Results from SELUTION SFA Trial Presented at JET
7.3 May 15, 2023: Terumo announces consolidated financial results for the fiscal year ended March 31, 2023
7.31 May 11, 2023: Medtronic to announce financial results for its fourth quarter and full fiscal year 2023
7.32 Apr 12, 2023: Medtronic has a layoff in California
7.33 Mar 28, 2023: Surmodics provides regulatory update on its strategy to submit an amended Premarket Approval Application for the SurVeil Drug-Coated Balloon
8 Appendix
8.1 Methodology
8.2 About GlobalData
8.3 Contact Us
8.4 Disclaimer
2.1 List of Tables
Table 1: PTA Peripheral DCB Catheters - Pipeline Products by Stage of Development
Table 14: AcoArt-Litos Drug-Eluting Balloon - A Post Market Clinical Study to Evaluate the Safety and Efficacy of the Acotec Drug-coated Balloon in the Treatment of the Below-the-knee Artery
Table 15: AcoArt-Litos Drug-Eluting Balloon - All Comers Post Market Clinical Follow-up to Continue the Surveillance of the Acotec Drug Coated PTA Catheter Orchid, Tulip and Litos in Lower Limb Treatment
Table 16: AcoArt-Litos Drug-Eluting Balloon - Comparison of Sirolimus Vs Paclitaxel Drug Eluting Balloon for Below-the-knee Angioplasty in Critical Limb Ischemia
Table 17: AcoArt-Tulip - A Post Market Clinical Study to Evaluate the Safety and Efficacy of the Acotec Drug-coated Balloon in the Treatment of the Below-the-knee Artery
Table 18: AcoArt-Tulip - All Comers Post Market Clinical Follow-up to Continue the Surveillance of the Acotec Drug Coated PTA Catheter Orchid, Tulip and Litos in Lower Limb Treatment
Table 31: Becton Dickinson and Co - Ongoing Clinical Trials Overview
Table 32: BD Sirolimus Drug Coated Balloon Catheter - A Prospective, Multicenter, Single Arm, Non-Randomized, Study to Assess the Performance and Safety of BD Sirolimus Drug Coated Balloon Catheter for Treatment of Femoropopliteal Arteries
Table 36: Boston Scientific Corp - Ongoing Clinical Trials Overview
Table 37: Ranger Paclitaxel-Coated PTA Balloon Catheter - Combination Therapy of Atherectomy Plus Drug-coated Balloon Versus Drug-coated Balloon for Complex Femoropopliteal Artery Disease (ARTEMIS Trial)
Table 38: Ranger Paclitaxel-Coated PTA Balloon Catheter - Drug-eluting Registry: Real-world Treatment of Lesions in the Peripheral Vasculature (ELEGANCE)
Table 39: Ranger Paclitaxel-Coated PTA Balloon Catheter - Efficacy of Rotational Atherectomy System Associated with Drug Coated Balloon Angioplasty (with or without Stent Placement) in the Management of Lower Limb Ischemia (ELLIPSE): Real Life Observational Study
Table 48: Peripheral Everolimus Drug-Coated Balloon - A First in-human Study Evaluating the Efficacy of Peripheral Everolimus Drug-coated Balloon in Patients with Peripheral Artery Disease: CVT-SFA
Table 53: Concept Medical Inc - Ongoing Clinical Trials Overview
Table 54: MagicTouch PTA Balloon Catheter - Comparison of Sirolimus Vs Paclitaxel Drug Eluting Balloon for Below-the-knee Angioplasty in Critical Limb Ischemia
Table 55: MagicTouch PTA Balloon Catheter - Head-to-Head Comparison of Sirolimus Versus Paclitaxel Drug-Eluting Balloon Angioplasty in the Femoropopliteal Artery
Table 56: MagicTouch PTA Balloon Catheter - Major Adverse Limb Events in Patients with Femoro-popliteal and Below-the-knee Peripheral Arterial Disease Treated with Either Sirolimus-coated Balloon or Standard Uncoated Balloon Angioplasty
Table 57: MagicTouch PTA Balloon Catheter - Randomized Controlled Trial of First SirolimUs Coated Balloon Versus Standard Balloon Angioplasty in the Treatment of Below the Knee Arterial Disease: FUTURE BTK
Table 58: MagicTouch PTA Balloon Catheter - Randomized Controlled Trial of First Sirolimus Coated Balloon Versus Standard Balloon Angioplasty in the Treatment of Superficial Femoral Artery and Popliteal Artery Disease
Table 59: MagicTouch PTA Balloon Catheter - Randomized Controlled Trial of Magictouch - Sirolimus Coated Balloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
Table 66: Cordis US Corp - Ongoing Clinical Trials Overview
Table 67: SELUTION SLR 018 DEB - Peripheral Artery Disease - Intervention with Selution SLR Agent Balloon for Endovascular Latent Limus Therapy for Failing AV Fistulas (ISABELLA) Trial
Table 68: SELUTION SLR 018 DEB - Peripheral Artery Disease - Pivotal Clinical Trial for the Treatment of Occlusive Disease of the Superficial Femoral Artery (SFA) Using SELUTION SLR Sirolimus-eluting Balloon
Table 69: SELUTION SLR 018 DEB - Peripheral Artery Disease - SAVE Trial - Use of the Selution Sirolimus Eluting Balloon for Dysfunctional AV accEss Treatment Indications
Table 70: SELUTION SLR 018 DEB - Peripheral Artery Disease - Scientific Proposal to Substantiate Vascular Effects Through Sirolimus vs. Paclitaxel DCB Implantation
Table 71: SELUTION SLR 018 DEB - Peripheral Artery Disease - SELUTION SLR 014 ISR: A Prospective Randomized Single Blind Multicenter Study to Assess the Safety and Effectiveness of the SELUTION SLR 014 Drug Eluting Balloon in the Treatment of Subjects with In-stent Restenosis
Table 72: SELUTION SLR 018 DEB - Peripheral Artery Disease - SUCCESS (Selution, Safety, Efficacy, Health Economics and Proms) PTA Study
Table 73: Dingke Medical Technology (Suzhou) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 83: FemFlow Drug-Eluting Peripheral Balloon Catheter (DEB) - Safety and Efficacy Study of FemFlow Drug-eluting Peripheral Balloon Catheter for Lesions with Femoral-popliteal Artery Stenosis or Occlusion: A Prospective, Multi-center, Objective Performance Criteria Clinical Trial
Table 103: Kinesyx-Based Peripheral Drug Coated Balloon - Product Status
Table 104: Kinesyx-Based Peripheral Drug Coated Balloon - Product Description
Table 105: Shanghai Easy-Flow Medical Tech Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 106: Below-The-Knee Rapamycin Drug Coated Balloon - Product Status
Table 107: Below-The-Knee Rapamycin Drug Coated Balloon - Product Description
Table 108: Shanghai Easy-Flow Medical Tech Co Ltd - Ongoing Clinical Trials Overview
Table 109: Below-The-Knee Rapamycin Drug Coated Balloon - To Evaluate the Safety and Efficacy of Drug-eluting Below-the-knee Balloon Dilatation Catheter in the Treatment of Infrapopliteal Artery Stenosis or Occlusion in a Prospective, Multicenter, Randomized Controlled Clinical Trial
Table 150: Zylox-Tonbridge Medical Technology Co Ltd - Ongoing Clinical Trials Overview
Table 151: Ultrafree Drug Coated PTA Balloon Catheter - BTK - A Prospective, Multicenter, Randomized Controlled Trail Using Drug-coated Balloon to Treat Below The Knee Arterial Stenosis or Occlusion
Table 152: Ultrafree Drug Coated PTA Balloon Catheter - Dialysis Access - Study to Evaluate the Safety and Efficacy of Ultrafree Drug Coated PTA Balloon Catheter for Dialysis Access
Table 153: Glossary 7
2.2 List of Figures
Figure 1: PTA Peripheral DCB Catheters - Pipeline Products by Stage of Development